Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
6(66.7%)
Phase 2
3(33.3%)
9Total
Phase 1(6)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT07540494Phase 1Not Yet Recruiting

Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects

Role: lead

NCT05800860Phase 2Completed

A Trial of GH001 in Patients With Treatment-resistant Depression

Role: lead

NCT05839509Phase 2Terminated

Phase 2 Clinical Trial of GH001 in Bipolar II Disorder

Role: lead

NCT05804708Phase 2Terminated

Phase 2 Clinical Trial of GH001 in Postpartum Depression

Role: lead

NCT06511947Phase 1Recruiting

Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects

Role: lead

NCT05753956Phase 1Completed

Safety and Pharmacokinetics of GH002 in Healthy Volunteers

Role: lead

NCT04698603Phase 1Completed

Clinical Study of GH001 in Depression

Role: lead

NCT04640831Phase 1Completed

Safety of GH001 in Healthy Volunteers

Role: lead

NCT05163691Phase 1Completed

Pharmacokinetics of GH001 in Healthy Volunteers

Role: lead

All 9 trials loaded